There has been considerable recent interest in the potential use of serum cystatin C as a diagnostic tool. Here we examined the hypothesis that the cystatin C level in the pleural effusion can differ from the corresponding serum level. We evacuated pleural effusion fluids from 47 patients by thoracentesis. Cystatin C, β 2 -microglobulin, inorganic phosphate, creatinine and total protein were quantified in both pleural effusion fluids and corresponding sera. We determined cystatin C levels in pleural effusions and calculated the ratio of cystatin C levels in serum and effusion, to discriminate between effusions caused by severe renal impairment and other types of effusion. Extremely high concentrations of cystatin C in serum/effusion pairs were only measured in patients with renal failure (6.0p0.8/6.0p0.8 mg/l, meanspS.D., n l 11). A clearly defined region was found to correspond to pleural effusion caused by renal failure (r l 0.954). The quantification of cystatin C in the effusion was justified by the discovery that there were some patients with a high serum cystatin C level but a low effusion concentration, or a low serum cystatin C but a high effusion concentration, indicating causes other than renal failure. In conclusion, the pilot data indicate a relationship between the cystatin C concentration in pleural fluid and the underlying disease. Thus cystatin C levels in pleural effusion and serum may be a valuable criterion for the differential diagnosis of pleural diseases of different aetiologies.
INTRODUCTION
Cystatin C is a recommended serological marker for renal function [1] [2] [3] . The advantage of serum cystatin C lies not in its sensitivity, but in its specificity. It is formed at a constant rate by nucleated cells and filtered by the kidneys. Circulating cystatin C concentrations can reflect variations in glomerular filtration rate throughout life, independent of age and sex [2] [3] [4] [5] .
Patients with renal dysfunction caused by acute or chronic kidney disease are particularly at risk of developing pleural effusion, which occurs in approx. 3 % of patients with uraemia [7, 8] due to pleuropneumonia as a consequence of reduced humoral and cellular immunity [6] , in 21 % of patients with altered oncotic pressure [9] , in 1.6 % of patients with fluid overload during peritoneal dialysis [10, 11] and in 21 % [12] to 51 % [13] of patients on long-term hemodialysis. The relative incidences of the various pulmonary diseases do not, however, appear to be related to a particular aetiology of chronic renal failure [6] . Despite the many laboratory tools that are available for the assessment of pleural effusion, a correct diagnosis may be difficult in multimorbid cases, and in up to 20 % of all patients with pleural effusions the aetiology remains unclear [14] .
In this clinical study, we provide data on the relationship between serum and pleural effusion levels of a number of high-and low-molecular-mass substances.
We simultaneously measured levels of cystatin C, β # -microglobulin [15] and phosphate in pleural effusion and serum, in addition to serum creatinine. We examined the hypothesis that the cystatin C level in the pleural effusion can differ from the corresponding serum level. We determined cystatin C levels in pleural effusions and calculated the ratio of serum to pleural effusion levels of cystatin C, in order to discriminate between effusions caused by severe renal impairment and other types of effusion. This observation has not been described previously. The ratio of cystatin C levels in serum and effusion may be complementary in diagnostics, and is therefore of clinical interest. We demonstrate here the diagnostic value of cystatin C measurements in pleural effusions.
METHODS
A total of 47 patients (28 male, 19 female ; age 64p12 years, meanpS.D.) took part in the study. All subjects gave informed consent for participation in the study, which was approved by the relevant ethical committee.
Pleural effusions were withdrawn by thoracentesis. In patients with established diseases, the following pleural effusions were studied : 11 malignant exudates (MAL), including one case of chylous fluid in metastatic carcinoma of the colon (MAL\CF), 10 parapneumonic effusions (PP), including two pleural empyemata (PP\ EM), and a total of 25 transudates due to congestive heart failure (CHF ; n l 7), cirrhosis (n l 7) or renal failure (n l 11). Impaired renal function was associated with nephrotic syndrome in four patients, diabetic nephropathy in four patients, vascular nephrosis in two patients and nephrosclerosis in one patient. The diagnoses of the underlying diseases were established by the patients' histories, clinical, radiological and laboratory investigations (e.g. total protein, phosphate, white cell count ; see also Table 1) , and cytological examinations of the pleural fluids. In one case the diagnosis remained unclear (patient no. 27).
Venous blood samples were collected from all patients. Serum was prepared from blood samples, and aliquots of serum\effusion pairs were immediately used for nephelometric quantification of cystatin C and β # -microglobulin.
In some cases the serum\effusion pairs were stored at k20 mC for less than 1 week. It is known that cystatin C is stable over a number of weeks in serum at k20 mC. Serum creatinine was determined with a commercial assay based on the Jaffe method and a Hitachi 747 analyser, according to the manufacturer's instructions. P i , as an additional indicator of renal function, was quantified using a molybdate reaction (Phos Sys 3 Anorganischer Phosphor ; Boehringer Mannheim). The methods are generally accepted analytical methods for which assay performance is documented. The normal reference ranges for the clinical laboratory parameters are : serum cystatin C, 0.5-0.96 mg\l (N Latex Cystatin C ; Dade Behring, Marburg, Germany) [5, 16] ; β # -microglobulin, up to 2.5 mg\l (L Latex β2-Microglobulin ; Dade Behring) ; creatinine, 2.6-4.5 mg\dl ; P i , 2.7-4.5 mg\dl. Concentrations of total protein were quantified spectrophotometrically at 546 nm after reaction with an alkaline copper sulphate solution (Biuret reagent).
Statistical methods
Statistical analysis was performed on a MacIntosh computer using the statistical software package StatView 4.52 (Abacus Concepts Inc., Berkeley, CA, U.S.A.). Data were expressed as mean valuespS.D.
Even the simplest experimental situation involving the comparison of two means requires either a long sequence of relevant previous records that were not available or a random sampling assumption. With random sampling, a widely used non-parametric test for the difference in location of two distributions is that of Wilcoxon. The standard Wilcoxon's Signed Rank Test was applied to the data to establish a significant difference between clinical laboratory parameters. The combined samples were ranked in order of size from smallest to largest. The sum of the ranks was calculated for the samples and an approximate significance level was obtained by referring to tables. Wilcoxon's test is not really distribution-free. It assumes the random sampling hypothesis, but it does not assume that the populations that are randomly sampled are normal. This test is justified here on the assumption of certain symmetries in the joint error distribution of all the errors considered simultaneously. With random sampling, this joint distribution has the property of being obtained by multiplying the individual distributions. In other words, the performance of the distribution-free test does not depend on the choice of the individual distribution function. It is the act of randomization, and not the introduction of a ' distributionfree ' test function, that plays the major role in making the procedure insensitive to distribution assumptions. For random sampling from normal distributions, we refer to Student's t test. In particular, given n A observations with treatment A and n B with treatment B, the t quantity would be distributed in Student's t distribution with v l n A jn B k2 degrees of freedom. This distribution provides a reference set by which the plausibility of any contemplated value of the difference in means can be judged. The procedure has the advantage that the reference set is generated from the samples themselves. Further, regression curves can be found by linear regression analysis for many pairs of related observations, such as the concentrations of cystatin C in pleural effusions and sera shown in Figure 1 and the relationships between serum creatinine and cystatin C, P i and β # -microglobulin in pleural effusions depicted in Figure 2 . However useful the curves were, it was desirable to have a quantitative measure of how closely two variables were related, and the standard Pearson correlation coefficient provides such a measure. It is the ratio of the covariance to the geometric mean of the n A and n B variances. Just as the variance is a measure of the deviations from the mean of a single set of observations, so the covariance is a measure of how the n A and n B deviations vary together. Thus if large positive n A deviations are associated with large negative n B deviations and vice versa, the covariance will be large and negative. There will be many terms in the numerator, which will be the product of a large positive and a large negative term. On the other hand, if the large positive n A and n B deviations and the large negative n A and n B deviations are associated, the covariance will be large and positive. If there is no particular association, however, the terms in the numerator will have different signs and will tend to cancel each other out, thus making the covariance small. Of course, the value for the correlation coefficient obtained from the samples is only an estimate of the true ' population ' correlation coefficient, and so is subject to some error. Values of P 0.05 were considered significant, where 1kP is the confidence interval. 
RESULTS
Pleural effusions occurred in approx. 10 % of patients hospitalized in our division. The frequency of pleural effusions was approx. 30 % among patients with severely impaired renal function. We studied 47 patients. A synopsis of the demographic and diagnostic data measured in the study is presented in Table 1 . The effusion volume collected ranged from 80 to 2550 ml. The serum creatinine concentration was raised above normal ( 1.3 mg\100 ml) in 23 patients. Serum P i above the normal value ( 4.5 mg\100 ml) was found in 12 of the 47 patients, and above-normal β # -microglobulin levels ( 2.5 mg\l) were measured in 31 of the 47 patients. Taken together, the mean cystatin C concentration (pS.D.) obtained when considering all pleural effusions did not differ significantly from that of the corresponding sera (2.7p2.0 and 2.6p2.1 mg\l respectively ; n l 47), as shown in Table 2 .
To study the correlation between serum and pleural cystatin C levels, we divided the patients into distinct subgroups based on their established diagnosis listed in the Methods section. First we looked at the cystatin C concentrations in pleural effusions of patients with diagnoses of MAL, PP and unknown, and compared them with serum values (Table 3) . The cystatin C concentrations were similar in sera and effusions, as indicated by their ratios being close to 1.0. The higher cystatin C concentrations in pleural effusions compared with sera in patients with CHF or cirrhosis (Table 3) were not significant at the P 0.05 level. However, pairing the observations from the experiments in the form of serum\effusion ratios for the same patients resulted in greater homogeneity than for the individual serum and effusion values. By confining t-test comparisons within such blocks (pairing is a special case of blocking), greater precision could be obtained. In the paired design the block size was 2. The relevant error arose only from differences between adjacent observations, and this was considerably less (column 5 of Table 3 ) than the error with the unpaired design (columns 3 and 4 of Table 3 ), which measured differences among all the observations. In the unpaired design the reference t distribution had 12 degrees of freedom, whereas for the paired design it had only six degrees of freedom. We profited from the paired design because the decrease in the variance (S. D.) obtained by pairing outweighted the effect of the decrease in the number of degrees of freedom of the distribution. Although blocking and randomization were valuable means of dealing with unavoidable sources of variability, here we relied on the assumption of sampling from normal distributions. However, the small body of data did not converge on a solution, indicating that the populations randomly sampled were normally distributed as surely and expeditiously as possible.
Cystatin C concentrations in all patients were above the normal range for the serum of healthy adults, with the exception of patients 7 (CHF), 10 (MAL), 16 (CHF), 21 (PP\EM), 29 (PP\EM), 30 (PP), 39 (MAL), 40 (PP) and 41 (MAL). Extremely high concentrations of cystatin C in effusion\serum pairs were, however, measured only in patients with renal failure (6.0p0.8\6.0p0.8 mg\l; n l 11). This is shown as a scatterplot in Figure 1 , which clearly indicates a recognizable region characteristic of pleural effusion associated with renal failure, with a regression coefficient (r#) of 0.91. The data show that the cystatin C level in pleural effusions can clearly discriminate between effusions caused by severe renal impairment and all other types of effusions. This observation has not been described previously. However, the practical importance of this finding is limited, because Figure 1 also demonstrates that the diagnostic discrimination obtained by determining the concentration of cystatin C in pleural effusions is much poorer than that obtained using the serum concentration of this analyte. The range of cystatin C concentrations in the effusions from renally impaired patients was approx. 4-8 mg\l, compared with 0.5-4 mg\l for ' other ' patients ; the corresponding values for serum cystatin C concentrations were 4.8-7.5 and 0.5-3 mg\l respectively.
The quantification of effusion cystatin C was justified by the discovery that there was a patient with a high serum cystatin C level but a low effusion concentration, and others with low serum cystatin C but high effusion concentrations, indicating that there were causes for this other than renal failure. In the patient with a high serum but a low effusion cystatin C concentration, the cause of pleural disease was chylous pleural fluid (MAL\CF : metastasis of a colon carcinoma). The presence of a pleural empyema (PP\EM) was quantified by a low serum cystatin C level but a high effusion concentration.
We also established significant positive correlations between pleural effusion cystatin C and pleural effusion β # -microglobulin (r l 0.960, P 0.0001), and between cystatin C and P i in the pleural effusion (r l 0.704, Table 4 ). Consistently high concentrations of cystatin C in serum\effusion pairs were found in patients with impaired renal function only. The levels of cystatin C, P i and β # -microglobulin in pleural effusions showed significant correlations with that of serum creatinine, as depicted in Figure 2 . Moreover, Figure 2 indicates that serum creatinine and effusion β # -microglobulin were comparable with cystatin C in their diagnostic discriminatory power in cases of pleural effusions caused by renal failure. However, the detailed investigation of β # -microglobulin levels in serum and pleural effusion was beyond the scope of this paper.
DISCUSSION
There has been much recent interest in the potential use of serum cystatin C as a diagnostic tool. Although cystatin C is found in a variety of human body fluids, such as spinal fluid, milk, seminal plasma and bronchoalveolar lavage fluid [17] , glomerular filtration appears to be the only elimination mechanism. Depending on the degree of impairment of renal function, this lowmolecular-mass protein (13.25 kDa) accumulates in both the blood and plasmatic filtrates, since it passes readily through body membranes. Cystatin C has been demonstrated to specifically reflect impaired renal function, as it accumulates in the serum as the glomerular filtration rate decreases. This relationship is what one might expect ; indeed, it is rather obvious. However, it has also been reported that serum cystatin C may be elevated in malignant and rheumatic diseases [18, 19] . In such cases, high serum cystatin C levels may be due to enhanced inflammation, malignant cell damage or nephrotoxic treatment. However, pleural effusion, when occurring in such states, is generally exudative in nature. Thus cystatin C concentrations in serum alone are of limited value. Determination of the concentrations of a number of high-and low-molecular-mass substances in effusions is not superfluous, as the serum concentrations alone do not allow a relatively reliable diagnosis of pleural diseases.
There have been a few evaluations of cystatin C levels in serum, but the present paper is the first to investigate cystatin C levels in pleural effusions. Further, we provide for the first time data on the relationship between serum and pleural effusion cystatin C levels.
Cystatin C levels in serum and pleural effusion are highest in patients with renal failure (Table 3 ). The present study is the first to show a clearly defined region, with high cystatin C values corresponding to pleural effusion caused by renal failure (Figure 1 ). This is in contrast with cystatin C concentrations in pleural effusions of any other aetiology. We obtained this result by correlation analysis of serum and pleural effusion levels of cystatin C. As a new diagnostic parameter, the combination of a transudative effusion (total protein 3.0 g) with a high cystatin C concentration points towards a renal aetiology for the pleural effusion, rather than CHF or cirrhosis. In contrast, high cystatin C concentrations in both serum and pleural effusion of exudative character (total protein 3.0 g) combined with renal failure are more likely to be due to uraemic pleuritis. This is important, because pleural effusions are common in end-stage renal disease. Tests to distinguish uraemic from other types of effusion would be quite helpful. Based on our work (in 47 patients, only 11 of whom displayed renal failure), it is not possible to differentiate the possibility that cystatin C levels are high in renal failure from the possibility that, in the presence of other types of effusion, a high cystatin C level indicates renal failure. We also cannot exclude a third possibility, i.e. that a patient with renal failure who then develops some other type of effusion will also have a high cystatin C level. However, our data could not confirm increased serum cystatin C levels in patients with liver cirrhosis, as reported by Woitas et al. [20] , because none of our cirrhotics had renal failure.
The cystatin C concentrations for the patient presenting with chylous fluid give an example of a high serum cystatin C level but a low effusion concentration (Table 3) . On the other hand, two patients with parapneumonic pleural effusions show a low serum cystatin C level but a high effusion concentration (pleural empyema). The normal serum cystatin C level in these patients might be caused by enhanced migration of cystatin C-containing leucocytes to the pleural cavity. Nilsson et al. [21] confirmed the presence of cystatin C and other low-abundance proteins in a patient with severe parapneumonic pleural effusion, using a combination of analytical methods. It is suggested that systemic inflammation and leucocyte counts in both serum and pleural effusion are possible mechanisms responsible for this increase. Pulmonary congestion due to CHF may cause elevated cystatin C levels in serum and effusion, in addition to associated renal dysfunction. The mechanism of increased cystatin C levels in patients with cirrhosis is not completely understood, but an impaired glomerular filtration rate seems to be the mechanical factor involved (see [20] ).
In our study, both instances in which the ratio of serum to pleural cystatin C differed from approx. 1.0 were related to causes of pleural disease other than renal failure, CHF or cirrhosis. We studied only a small number of patients, as only the more severe cases result in pleural effusion. Nevertheless, the quantification of effusion cystatin C and the ratio between serum and pleural levels of this protein show the value of determining cystatin C concentrations in pleural effusions, in order to facilitate the differential diagnosis of pleural diseases. The observation that changes in the β # -microglobulin levels in the serum and effusion correspond with those of cystatin C points to the diagnostic value of this parameter also ; however, the detailed investigation of β # -microglobulin levels in serum and effusion was beyond the scope of this paper.
In conclusion, our work points to the usefulness of the simultaneous quantification of cystatin C in both serum and pleural effusion. The cystatin C level in the pleural effusion can differ from the corresponding serum level, and serum cystatin C alone does not suffice to discriminate between the aetiologies of pleural effusions. In particular, we aimed to establish whether the ratio of serum to effusion cystatin C observed in patients with different pleural diseases can be accompanied by an increased value above 1 or, conversely, by a decrease to a value below 1. Our findings suggest that the ratio between serum and pleural effusion levels of cystatin C might be useful in differentiating between various pleural diseases. In view of the small scale of our clinical pilot study, we do not overestimate our novel findings, and restrict ourselves to the observations of our cases. The following are possible mechanisms that could explain our findings : (i) an impaired glomerular filtration rate, with or without enhanced uraemic inflammation (uraemic pleuritis) ; (ii) enhanced cell turnover and\or malignant cell damage (MAL) ; (iii) lesion of the thoracic duct plus malignant cell damage (MAL\CF) ; (iv) highly purulent inflammation within the pleural cavity with excessive cell detritus (PP\EM), whereby the normal serum cystatin C level might be due to enhanced migration of cystatin C-containing leucocytes to the pleural cavity ; (v) increased local inflammation and systemic leucocytosis (PP) ; (vi) pulmonary congestion and incipient renal failure as a potential cause of elevated cystatin C in both serum and effusion (CHF) ; (vii) an impaired glomerular filtration rate in patients with cirrhosis leading to elevated cystatin C levels (see [20] ).
